Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.

Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Columns

From the President’s Desk

September 2024—The use of artificial intelligence in medicine is spreading rapidly, but it’s not entirely new. Tools that incorporate AI have been approved by the FDA since the mid-1990s, mostly for use in radiology and cardiology. Like all of our colleagues in medicine, we pathologists have been hearing a lot about AI lately. Some of us are excited about it, and most of us are familiar with the surge of hype claiming that AI will change everything about how we practice.

Clinical pathology selected abstracts

September 2024—Syphilis, an infectious disease caused by the spirochete bacterium Treponema pallidum, can be transmitted by blood transfusion. Therefore, donor blood has been routinely screened for syphilis since the 1950s. Although a case of transfusion-transmitted syphilis has not been documented in more than 50 years, routine serological testing is still performed because there is not sufficient evidence that it is no longer necessary. Syphilis testing can contribute to disease monitoring for overall public health by identifying infected blood donors so they can seek treatment to prevent further spread. The Transfusion Transmissible Infections Monitoring System (TTIMS) monitors infectious disease and demographic changes in donors who contribute approximately 60 percent of the U.S. blood supply, including at four major blood-collection organizations.

Anatomic pathology selected abstracts

September 2024—Research has shown assessment of tumor-associated stroma to be of reliable prognostic value. The authors conducted a study in which they evaluated the prognostic value of tumor-stroma ratio in a large multicenter cohort of nasopharyngeal carcinoma. They used the conventional H&E-stained slides of 115 cases of nasopharyngeal carcinoma to assess tumor-stroma ratio as described in recent guidelines. The amount of tumor-associated stroma was assessed as a percentage and then tumors were classified as stroma high (more than 50 percent) or stroma low (50 percent or less). Kaplan-Meier curves, a χ2 test, and Cox regression univariable and multivariable analyses were conducted.

Molecular pathology selected abstracts

September 2024—Oncology patients may benefit greatly from whole genome sequencing. Previous studies have suggested that it can provide relevant information pertaining to pediatric cancers, especially in selected cohorts of patients with high-risk disease. However, its clinical utility has not been thoroughly explored in routine clinical practice. The authors of this study examined the benefits of whole genome sequencing (WGS) in a consecutive cohort of pediatric patients from two institutions who required molecular workup for hematological neoplasms and solid tumors. Great Ormond Street Hospital, London, and Cambridge (England) University Hospitals offered WGS to patients with leukemia or solid tumors, respectively.

Q&A column

September 2024
Q. When performing body fluid cell counts, we report total nucleated cells and RBCs. What cell categories should we report on the corresponding differential? Can we group together monocytes, macrophages, and mesothelial cells since it is difficult to distinguish reactive mesothelial cells from monocytes and macrophages? If so, what category name should be applied? Should we report mesothelial cells as a comment or include them in the differential? Read answer.
Q. Are nonlaboratory personnel who perform point-of-care testing required to be tested for visual color discrimination? Or is it sufficient that personnel pass a functional assessment during their competency evaluation to evaluate their ability to provide an accurate result on tests that require interpreting colors? Read answer.

Newsbytes

September 2024—The ARUP Institute for Research and Innovation in Diagnostic and Precision Medicine has created the Sherrie Perkins Research and Innovation Collaboration grant to fund lab medicine research that has the potential to significantly improve patient care.

Put It on the Board

September 2024—The Association for Molecular Pathology and pathologist Michael Laposata, MD, PhD, announced on Aug. 19 the filing of a lawsuit challenging the Food and Drug Administration rule that regulates laboratory-developed test procedures as medical devices under the Federal Food, Drug, and Cosmetic Act. The lawsuit was filed in the U.S. District Court for the Southern District of Texas against the FDA; Robert M. Califf, MD, in his official capacity as commissioner of food and drugs; the U.S. Department of Health and Human Services; and Xavier Becerra, in his official capacity as secretary of HHS.

From the President’s Desk

August 2024—The CAP has been expanding its international footprint in recent years, and I hope to accelerate that trend during my presidency. The reason is simple: The CAP has established the world standard in quality for clinical laboratories, and it is our responsibility to share that standard as broadly as we can to improve care for patients everywhere in the world.

Clinical pathology selected abstracts

August 2024—Social media, including websites and platforms such as Facebook, Instagram, and X (formerly Twitter), are a dominant way to consume news and entertainment and have significant societal impact. Social media use in medicine, including pathology, is widespread and has been associated with numerous benefits. The medical industry generally has encouraged the professional use of social media, despite its potential harm. The approaches of various medical disciplines to social media have included support for early adoption, publication of how-to guides, enthusiastic backing by professional organizations, and formulation of guidelines to temper usage. The authors conducted a study to identify motivating forces and premises that underpin physicians’ adoption of social media for professional uses.

Anatomic pathology selected abstracts

August 2024—Emerging data suggest a correlation between T1 bladder cancer subcategorization, or substaging, and oncological outcomes. The International Society of Urological Pathology held a 2022 consensus conference on issues in bladder cancer, in Basel, Switzerland, in which it tasked a working group with making recommendations for T1 subcategorization of transurethral bladder resections. To this end, the ISUP developed and circulated a survey to its membership querying approaches for subcategorizing T1 bladder cancer. The survey focused on clinical relevance, pathological reporting, and endorsement of T1 subcategorization in the daily practice of pathology. Approximately 40 percent of respondents to the pre-meeting survey indicated that they do not routinely report the T1 subcategory.

MARKETPLACE

TRENDING